{
    "clinical_study": {
        "@rank": "92232", 
        "arm_group": [
            {
                "arm_group_label": "FishOil + placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and placebo capsule"
            }, 
            {
                "arm_group_label": "FishOil + CBE75", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and citrus bioflavonoids+vitamin E (CBE)(75 mg/capsule/day)"
            }, 
            {
                "arm_group_label": "FishOil + CBE150", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and CBE (150 mg/capsule/day)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this 8-week intervention trial is to investigate the effect of a dietary\n      supplement (containing citrus bioflavonoids and vitamin E) plus fish oil supplementation in\n      healthy hyperlipidemic subjects"
        }, 
        "brief_title": "Effect of Citrus Bioflavonoids/Vitamin E in Conjunction With Fish Oil Supplementation", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperlipidemia", 
        "condition_browse": {
            "mesh_term": "Hyperlipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  men and women \u2265 18 and \u2264 72 years old\n\n          -  generally healthy\n\n          -  BMI > 18 and < 38\n\n          -  LDL cholesterol \u2265 130 mg/dl and < 270 mg/dl\n\n          -  triglycerides \u2265 150 mg/dl and < 400 mg/dl\n\n          -  ability to understand and the willingness to sign a written informed consent\n\n        Exclusion Criteria:\n\n          -  use of nutritional supplements and medical foods for dyslipidemia within 30 days\n             prior to the study\n\n          -  use of omega-3 fatty acid dietary supplements within 30 days prior to the study\n\n          -  use of prescription HMG-CoA reductase inhibitors, bile acid sequestrants, fibrates,\n             cholesterol absorption blocking agents, or niacin\n\n          -  use of prescription medications and/or nonprescription medications for acute and\n             semi-acute medical conditions\n\n          -  history of cardiovascular disease, type i diabetes, autoimmune disease, liver or\n             kidney disease, malignancy, and serious mental illness.\n\n          -  known infection with HIB, TB, hepatitis B or hepatitis C\n\n          -  history of allergy or intolerance to study products\n\n          -  smoking, use of nicotine-containing products, or use of drugs of abuse 30 days prior\n             to the study\n\n          -  history of regular intake of > 14 alcoholic drinks per week for females and > 21\n             drinks per week for males"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "72 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671254", 
            "org_study_id": "POT2-FMR-CT"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "FishOil + placebo", 
                    "FishOil + CBE75", 
                    "FishOil + CBE150"
                ], 
                "intervention_name": "FishOil", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "FishOil + CBE75", 
                "intervention_name": "CBE75", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "FishOil + CBE150", 
                "intervention_name": "CBE150", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "FishOil + placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin E", 
                "Alpha-Tocopherol", 
                "Tocopherols", 
                "Tocotrienols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 20, 2012", 
        "location": {
            "contact": {
                "email": "josephlamb@metagenics.com", 
                "last_name": "Joseph J Lamb, MD", 
                "phone": "253-853-7207"
            }, 
            "facility": {
                "address": {
                    "city": "Gig Harbor", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98332"
                }, 
                "name": "Functional Medicine Research Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-blind, Placebo-controlled Trial of a Dietary Supplement Containing Citrus Bioflavonoids and Vitamin E at 2 Doses in Conjunction With Fish Oil Supplementation in Hyperlipidemic Subjects", 
        "overall_contact": {
            "email": "josephlamb@metagenics.com", 
            "last_name": "Joseph J Lamb, MD", 
            "phone": "253-853-7207"
        }, 
        "overall_contact_backup": {
            "email": "lincolnbouillon@metagenics.com", 
            "last_name": "Lincoln Bouillon, MBA", 
            "phone": "253-853-7206"
        }, 
        "overall_official": {
            "affiliation": "MetaProteomics / Metagenics / FMRC", 
            "last_name": "Joseph J Lamb, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in LDL cholesterol level at the end of 8 weeks", 
            "measure": "LDL cholesterol", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671254"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in triglyceride level at the end of 8 weeks.", 
                "measure": "Triglyceride", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 8 weeks"
            }, 
            {
                "description": "Change in oxidized LDL level at the end of 8 weeks.", 
                "measure": "oxLDL", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 8 weeks"
            }, 
            {
                "description": "Change in total cholesterol level at the end of 8 weeks.", 
                "measure": "Total cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 8 weeks"
            }, 
            {
                "description": "Change in HDL cholesterol level at the end of 8 weeks.", 
                "measure": "HDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 8 weeks"
            }
        ], 
        "source": "MetaProteomics LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MetaProteomics LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}